142 related articles for article (PubMed ID: 28470097)
21. Clinical and experimental applications of sodium phenylbutyrate.
Iannitti T; Palmieri B
Drugs R D; 2011 Sep; 11(3):227-49. PubMed ID: 21902286
[TBL] [Abstract][Full Text] [Related]
22. Glucose-induced beta cell dysfunction in vivo in rats: link between oxidative stress and endoplasmic reticulum stress.
Tang C; Koulajian K; Schuiki I; Zhang L; Desai T; Ivovic A; Wang P; Robson-Doucette C; Wheeler MB; Minassian B; Volchuk A; Giacca A
Diabetologia; 2012 May; 55(5):1366-79. PubMed ID: 22396011
[TBL] [Abstract][Full Text] [Related]
23. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
24. Chemical chaperon 4-phenylbutyrate protects against the endoplasmic reticulum stress-mediated renal fibrosis in vivo and in vitro.
Liu SH; Yang CC; Chan DC; Wu CT; Chen LP; Huang JW; Hung KY; Chiang CK
Oncotarget; 2016 Apr; 7(16):22116-27. PubMed ID: 26959118
[TBL] [Abstract][Full Text] [Related]
25. Class IIa HDACs do not influence beta-cell function under normal or high glucose conditions.
McCann J; Ellis M; McGee SL; Aston-Mourney K
Islets; 2019; 11(5):112-118. PubMed ID: 31112063
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells.
Larsen L; Tonnesen M; Ronn SG; Størling J; Jørgensen S; Mascagni P; Dinarello CA; Billestrup N; Mandrup-Poulsen T
Diabetologia; 2007 Apr; 50(4):779-89. PubMed ID: 17265033
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes.
Sharma S; Taliyan R
Pharmacol Res; 2016 Nov; 113(Pt A):320-326. PubMed ID: 27620069
[TBL] [Abstract][Full Text] [Related]
28. Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum-stress mediated apoptosis.
Vilatoba M; Eckstein C; Bilbao G; Smyth CA; Jenkins S; Thompson JA; Eckhoff DE; Contreras JL
Surgery; 2005 Aug; 138(2):342-51. PubMed ID: 16153446
[TBL] [Abstract][Full Text] [Related]
29. HDAC inhibitor 4-phenylbutyrate preserves immature phenotype of human embryonic midbrain stem cells: implications for the involvement of DNA methyltransferase.
Khan Z; Akhtar M; Ekström TJ
Int J Mol Med; 2011 Dec; 28(6):977-83. PubMed ID: 21894430
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase regulates insulin signaling via two pathways in pancreatic β cells.
Kawada Y; Asahara SI; Sugiura Y; Sato A; Furubayashi A; Kawamura M; Bartolome A; Terashi-Suzuki E; Takai T; Kanno A; Koyanagi-Kimura M; Matsuda T; Hashimoto N; Kido Y
PLoS One; 2017; 12(9):e0184435. PubMed ID: 28886131
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic potential of selective histone deacetylase 3 inhibition.
Zhang L; Chen Y; Jiang Q; Song W; Zhang L
Eur J Med Chem; 2019 Jan; 162():534-542. PubMed ID: 30472601
[TBL] [Abstract][Full Text] [Related]
32. Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line.
Kusaczuk M; Krętowski R; Bartoszewicz M; Cechowska-Pasko M
Tumour Biol; 2016 Jan; 37(1):931-42. PubMed ID: 26260271
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics.
Meier BC; Wagner BK
Epigenomics; 2014 Apr; 6(2):209-14. PubMed ID: 24811789
[TBL] [Abstract][Full Text] [Related]
34. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress.
Kubota K; Niinuma Y; Kaneko M; Okuma Y; Sugai M; Omura T; Uesugi M; Uehara T; Hosoi T; Nomura Y
J Neurochem; 2006 Jun; 97(5):1259-68. PubMed ID: 16539653
[TBL] [Abstract][Full Text] [Related]
35. Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity.
Gardian G; Yang L; Cleren C; Calingasan NY; Klivenyi P; Beal MF
Neuromolecular Med; 2004; 5(3):235-41. PubMed ID: 15626823
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside.
Hornig E; Heppt MV; Graf SA; Ruzicka T; Berking C
Exp Dermatol; 2016 Nov; 25(11):831-838. PubMed ID: 27792246
[TBL] [Abstract][Full Text] [Related]
37. Induction of histone acetylation and growth regulation in eryrthroleukemia cells by 4-phenylbutyrate and structural analogs.
Lea MA; Randolph VM; Hodge SK
Anticancer Res; 1999; 19(3A):1971-6. PubMed ID: 10470142
[TBL] [Abstract][Full Text] [Related]
38. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
39. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis.
Petri S; Kiaei M; Kipiani K; Chen J; Calingasan NY; Crow JP; Beal MF
Neurobiol Dis; 2006 Apr; 22(1):40-9. PubMed ID: 16289867
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis.
Chou DH; Holson EB; Wagner FF; Tang AJ; Maglathlin RL; Lewis TA; Schreiber SL; Wagner BK
Chem Biol; 2012 Jun; 19(6):669-73. PubMed ID: 22726680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
